Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting

Jessica Paken1*, Cyril D. Govender1, Mershen Pillay1,2 and Vikash Sewram3*

Abstract

Background: Ototoxicity monitoring is uncommon in South Africa, despite the increased use of ototoxic medication to manage the burden of disease in the country. The successful implementation of such a protocol requires cognisance of contextual realities and multiple dimensions for consideration from both patients and service providers. As part of an ongoing cohort study on cisplatin-associated ototoxicity and efforts to better inform the implementation of such programmes, the perspectives of cervical cancer patients and healthcare workers towards ototoxicity monitoring were assessed.

Methods: This concurrent-triangulation mixed-methods study was conducted at a tertiary hospital in South Africa. Self-reported questionnaires from patients (n = 80) and healthcare personnel comprising clinicians, oncology nurses, pharmacists, and radiotherapists (n = 32), results of audiological evaluations, researcher field notes, and estimated patient and service provider costs contributed to data for this study. Data analysis included descriptive statistics, comparison of test characteristics and deductive thematic analysis.

Results: The ototoxicity monitoring programme was positively received by the participants, with 90.6% of healthcare personnel and 89% of patients reporting it to be beneficial. The clinicians (76.6%) were identified as the main providers of information on the effects of chemotherapy medication and made the necessary referrals for audiological evaluation. The approximate cost of setting up such a programme included purchase of equipment (US$56 700) and the appointment of an audiologist (US$ 26 250). The approximate costs to patients included transport costs (US$ 38) and the loss of income for the day (US$ 60), calculated at the minimum wage per hour, if employed. Creative appointment scheduling, easy facility access and detailed locally comprehensible counselling improved patient compliance to the programme. Whilst the sequential use of American Speech-Language-Hearing Association (ASHA) and National
Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria aided in an evidence-informed approach to aural rehabilitation, DPOAEs and speech discrimination displayed low sensitivity (range 1.45% – 22.39%) but high specificity (range 77.78% – 100%) when identifying ototoxic change.

Conclusion: This novel study, through a ‘real-world’ experience, has revealed that an ototoxicity monitoring programme is feasible in South Africa, through meaningful engagements with- and considerations from- patients and service providers regarding planning, delineation of responsibilities and cost implications. The findings can potentially serve as a roadmap for other limited resource environments.

Keywords: Audiological assessment, Ototoxicity, Monitoring programme, Cisplatin, Cervical cancer, South Africa, Hearing loss

Introduction

More than 5% of the world’s population (approximately 432 million adults) currently has a disabling hearing loss, with this estimation likely to increase to 10% (over 700 million) by 2050 [1]. Some of the more significant contributors to the increasing global estimates for disabling hearing impairment are longer lifespans, greater exposure to recreational and occupational noise, and ototoxicity [2]. Ototoxicity is defined as the chemical injury to the structures and functioning of the auditory-vestibular system occurring as a side effect of pharmacotherapy and exposure to chemicals and ionizing radiation [3]. With over 600 drugs considered to be ototoxic, the most commonly used include the platinum-based chemotherapeutic agents (cisplatin and carboplatin), aminoglycoside antibiotics, loop diuretics, macrolide antibiotics, antimalarials [4], and antiretroviral medication [5].

Cisplatin, known as the “Penicillin of cancer” [6], is used in the treatment of many cancers [7] but is also notorious for its ototoxic properties, with the reported prevalence varying between 50–80% and 60–90% in adults and children, respectively [8]. It is well documented that hearing loss, and especially an untreated one, can adversely impact the quality of life of affected individuals [9, 10], but is more overwhelming at a time when their critical healthcare decisions are discussed [11], and significant others rally together to provide support [12]. Therefore, early detection of hearing loss and proactive management and care through an ototoxicity monitoring programme is essential [13].

Ototoxicity monitoring in South Africa should be an integral component within the audiologist’s scope of practice, especially given the country’s burden of disease profile within the communicable (Human Immunodeficiency Virus, Multi-Drug Resistant Tuberculosis), and non-communicable (Cancer, Diabetes, Hypertension) disease envelope. Despite international guidelines for ototoxicity monitoring [14] being published almost 26 years ago, the Speech-Language and Hearing Professions Board of the Health Professions Council of South Africa (HPCSA) only released its guidelines in 2018 [15].

Ototoxicity monitoring, with nationally accepted guidelines, is yet to become part of mainstream practice, globally [16]. By way of examples, in New Zealand, it was found that there was no nationally accepted ototoxicity monitoring programme and the need for closer collaboration between oncologists and audiologists were identified [17]. Oncologists and infectious disease physicians in the USA were also found not to be fully aware of the diversity of an audiologist’s practice, potentially influencing the success of an ototoxicity monitoring programme [12]. Similar findings were evident in the UK, even amongst audiologists (71%) who were not aware of an ototoxicity monitoring programme within their services and baseline assessments only being conducted following patient’s auditory complaints [18]. A survey in South Africa revealed a need for oncologist’s education on ototoxicity and its importance on the survivor’s quality of life [19]. A more recent study revealed that healthcare personnel, managing cancer patients, need to improve their awareness of ototoxicity, with audiologists requiring greater awareness of monitoring programmes [20]. Similar sentiments were expressed by Khoza-Shangase and Masondo [21], who also added that audiologist’s training in ototoxicity monitoring, i.e., assessment and management, has not translated well to their practices within the South African context.

The national guidelines for South Africa, issued by the HPCSA in 2018 [15], and based primarily on American Speech-Language-Hearing Association (ASHA) [14] and American Academy of Audiology (AAA) [22] protocols represents a well-structured approach for monitoring ototoxicity. However, human resource and infrastructure constraints [23] hamper the efficient rollout of this programme and therefore, a more locally responsive programme cognisant of the contextual realities of the environment [21] is paramount to successful implementation. Furthermore, there has been no formally implemented ototoxicity monitoring programme to identify and monitor ototoxicity in patients receiving cancer chemotherapy, despite global projections reporting a 47% increase by 2040 [24]. It is also estimated that by 2040, the incidence...
of cancer in South Africa will increase by 60.8% with cancer of the cervix (disease with which the current patient cohort is defined) projected to increase by 48% [25].

This investigation, which adopted a concurrent triangulation mixed-methods approach, formed part of an ongoing cohort study on cisplatin-associated ototoxicity. The aim was to assess the perspectives of cervical cancer patients and their healthcare team towards ototoxicity monitoring, with a view to further informing feasibility, implementation, and integration of an ototoxicity monitoring programme into the clinical environment.

**Methods**

**Study site and population**

The study was conducted at a tertiary level referral hospital in KwaZulu-Natal, South Africa.

This site was selected due to its large referral base, providing highly specialized healthcare to the Western half of the province. Being one of the main referral centres for cancer patients and having an Audiology department deemed this site most suitable to achieve the aim of this study.

The study participants included:

- 80 females diagnosed with incident cervical cancer, and
- 32 healthcare personnel [six clinicians (oncologists and registrars) working within the oncology department, eight oncology nurses, nine pharmacists, and nine radiotherapists].

**Participant recruitment and data collection**

All cases of cervical cancer meeting the eligibility criteria of an incident diagnosis were invited to participate. Women either presenting with profound hearing loss at baseline assessment, having received previous cisplatin chemotherapy, or a history of tuberculosis and/or malaria, were excluded. Prospective data collection on ototoxicity monitoring took place over a two-year period followed by a holistic, detailed reflection of the monitoring process within this institutional context. The healthcare personnel within the Oncology Department were also invited to participate in this phase of the study.

Acceptability of the ototoxicity monitoring programme was determined through the completion of questionnaires by healthcare personnel and patients at the end of the study and follow-up period, respectively. The questionnaire aimed to solicit information on the participants’ experiences and the operational processes involved in the ototoxicity monitoring programme. The questionnaire was developed taking into consideration the ASHA [14], AAA [22] and HPCSA [15] guidelines for the management of patients receiving ototoxic medication, which delineated the roles of each of the key stakeholders in an ototoxicity monitoring programme. Literature [7–9, 12, 16] (highly cited articles in the field of ototoxicity) was also used to inform us about key variable selection. The questionnaire was constructed in English, translated into isiZulu and back-translated into English to ensure consistency. The questionnaire was also piloted prior to the study. Modifications were thereafter made, and any ambiguities or inconsistencies were addressed. A working definition of feasibility in the current study involved a consideration of acceptability (costs to patient and service provider) and appropriateness (through infrastructure and logistical requirements). Researcher field notes, obtained via direct observation (written immediately after leaving the field) and inference (reflecting social relationships, emotions, and meanings), as described by Neuman [26], were also used to provide insight. Potential implicit and explicit bias resulting from this process were managed using the methodology of Deggs and Hernandez [27] to ensure that the research setting was not misunderstood, misinterpreted, or misconstrued. Furthermore, the use of structured field notes also facilitated a self-reflective process allowing the researcher to be constant and systematic during data collection [27]. The time taken for each audiological evaluation was determined through the use of the participant’s tracking document which also captured the duration of each audiological procedure and evaluation.

Ototoxicity monitoring included the following audiological procedures which were conducted at all audiological evaluations namely baseline, after three-cycles of cisplatin chemotherapy, and at one-, three- and six-month post-treatment: case history interview, otoscopic examination, immittance audiometry (tympanometry and acoustic reflex threshold testing), pure tone audiometry (conventional and extended high frequency range), speech audiometry (speech reception threshold testing and word recognition score testing) and Distortion product otoacoustic emission (DPOAE). All audiological procedures were undertaken in accordance protocols for ototoxicity monitoring prescribed by the American Speech-Language and Hearing Association [14]. Immittance audiometry was conducted using the GSI Tymstar V2 Impedance meter, pure tone audiometry was conducted in a soundproof booth using the Madsen Astera clinical audiometer (GN Otometrics, Schaumburg, IL, USA) and the Maico otoacoustic emissions were used for the acquisition of DPOAE data [28]. For the WRS testing, the CID W-22 Auditory test word list (Supplementary file 1) was used for English-speaking patients whilst an IsiZulu wordlist (Supplementary file 2), collated in the Discipline of Audiology, was used for IsiZulu-speaking patients.
patients. The audiometric soundproof booth and the twin channel audiometer, as described for pure tone audiometry, were used.

Patient costs were estimated based on direct non-medical costs such as transportation and income loss (employed) for the day. Loss of income was estimated using the official minimum wage categories reflected in the National Minimum Wage Act in the South African Government Gazette [29]. Transport costs (US$7.69) were based on public transport estimates for a ‘home-to-hospital’ return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.

Data analysis
Descriptive statistics for the quantitative analysis of the questionnaires was conducted using the STATA 15 software (StataCorp. 2017, Texas, USA). Clinical analysis of questionnaires was conducted using the STATA 15 software. Descriptive statistics for the quantitative analysis of the health facility's return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.

Data analysis
Descriptive statistics for the quantitative analysis of the questionnaires was conducted using the STATA 15 software (StataCorp. 2017, Texas, USA). Clinical analysis of questionnaires was conducted using the STATA 15 software. Descriptive statistics for the quantitative analysis of the health facility's return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.

Data analysis
Descriptive statistics for the quantitative analysis of the questionnaires was conducted using the STATA 15 software (StataCorp. 2017, Texas, USA). Clinical analysis of questionnaires was conducted using the STATA 15 software. Descriptive statistics for the quantitative analysis of the health facility's return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.

Data analysis
Descriptive statistics for the quantitative analysis of the questionnaires was conducted using the STATA 15 software (StataCorp. 2017, Texas, USA). Clinical analysis of questionnaires was conducted using the STATA 15 software. Descriptive statistics for the quantitative analysis of the health facility's return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.

Data analysis
Descriptive statistics for the quantitative analysis of the questionnaires was conducted using the STATA 15 software (StataCorp. 2017, Texas, USA). Clinical analysis of questionnaires was conducted using the STATA 15 software. Descriptive statistics for the quantitative analysis of the health facility's return journey within a 50 km radius. Cumulative costs were calculated over an 8-h day for the total number of visits (5) to the health facility.

Direct service provider costs were based on the minimal audiological equipment and human resource requirements. Equipment costs were calculated from quotations received from the three major suppliers of audiological equipment in South Africa. The human resources estimate was based on the annual remuneration cost of an entry-level audiologist. Cost information (in South African Currency) was converted to $US using an exchange rate: US$1 = ZAR13.
Results
The median age of the patient cohort was 52 years (range 32–79 years). Thirty-seven (45.1%) participants presented with stage IIB, 29 (35.4%) presented with stage IIIB cervical cancer, whereas stage IA, IB, and IIIA were less common (less than 4% each). Sixty-eight participants (82.9%) presented with co-morbidities, of which 44 (64.7%) were HIV positive and on ARTs. Patients had varied sources of income, viz. old age grants (26%), domestic workers (45%) and the remaining being unemployed (29%).

Acceptability
Patient feedback on key aspects relating to their experience in a monitoring programme is provided in Table 1. It was reported that a large proportion (58.8%) of patients were informed about the effects of chemotherapy medication prior to treatment and that clinicians and audiologists were the main providers of such information and made the necessary referrals for audiological evaluation, respectively. Whilst 52.5% of the patients indicated that the battery of tests were time-consuming, the majority of patients followed through on the recommendations of the audiologist, the most common of which included counselling (57.5%) or referral for a hearing aid evaluation and tinnitus management (23.8%). Seventy-one participants (89%) reported having benefitted from the monitoring programme.

Healthcare worker responses revealed that clinicians (50%), oncology nurses (62.5%) and radiotherapists (88.9%) treated between 70 to 100 cervical cancer

Table 1  Patient experience of the ototoxicity monitoring programme

| Questions                                                                 | Responses – n (%)                  |
|--------------------------------------------------------------------------|-----------------------------------|
| 1. Did you receive information about the ototoxic effects of the chemotherapy medication before commencing with treatment? | No – 33 (41.3)  Yes – 47 (58.8)    |
| 2. Who provided you with the information?                                 | Nurse – 3 (6.4%)  Oncologist/clinician – 36 (76.6) |
|                                                                          | Oncologist – 7 (14.9)  Pharmacist – 0 |
|                                                                          | Radiotherapist – 1 (2.1)  Audiologist – 7 (14.9) |
| 3. Who referred you for ototoxicity monitoring?                           | Nurse – 3 (3.8)  Oncologist/clinician – 32 (40.0) |
|                                                                          | Oncologist/clinician – 32 (40.0)  Pharmacist – 1 (1.3) |
|                                                                          | Pacific - 0    Radiotherapist – 4 (5)  Audiologist – 40 (50) |
| 4. Were the audiological evaluations conducted on the same day as your chemotherapy? | No – 53 (66.3)  Yes – 6 (7.5)  Sometimes – 21 (26.3) |
| 5. Do you feel that the duration of the audiological testing was too long? | No – 38 (47.5)  Yes – 42 (52.5)  |
| 6. Were the results of the audiological evaluations clearly explained to you? | No - 0 (0)  Yes – 80 (100.0)  |
| 7. Which of the following recommendations were made?                      | Hearing aid evaluation – 3 (3.8)  Counselling – 46 (57.5) |
|                                                                          | Tinnitus management – 3 (3.8)  Combination of all – 5 (6.3) |
|                                                                          | Hearing aid evaluation and counselling – 4 (5.0)  Hearing aid evaluation and tinnitus management – 19 (23.8) |
| 8. Did you follow-up on any of the above recommendations made?            | No -1 (1.3)  Yes – 76 (95.0)  Sometimes – 3 (3.8) |
| 9. Do you feel that the monitoring of your hearing during chemotherapy was beneficial | No – 3 (3.8)  Yes – 71 (88.8)  Do not know – 6 (7.5) |
patients during this two-year study period (Table 2). As per the responses received, oncology nurses (75%) and clinicans (67%) were found to be the providers of information on the ototoxic effects of medication. Enquiring about a patient’s hearing history did not emerge as common practice, with only one clinician (16.7%) and one nurse (12.9%) reporting positively. Despite more than 90% of the healthcare personnel acknowledging the benefits of an ototoxicity monitoring programme, there were varied responses to a team approach in patient management as most healthcare personnel referred less than 20 patients to the audiologist in the previous year.

A review of the researcher field notes further corroborated evidence that both patients and healthcare personnel predominantly displayed a positive attitude towards ototoxicity monitoring. The field notes also assisted in identifying key aspects to making the programme locally responsive; thereby, enhancing acceptability and appropriateness within the affected cohort (Table 3). Patients were found to take greater responsibility for their hearing health by actively participating in the programme, adhering to follow up appointments and being more forthcoming about their symptoms and other risk factors for ototoxic hearing loss. In the event where follow-up appointments could not be kept, patients even took initiative of rescheduling on their own accord. The interactional processes amongst health care personnel revealed a need for their roles within the programme to be well-defined and providing written feedback from the audiologist to the referring source encouraged a collaborative team approach.

Time On average, eight patients were monitored weekly. With the average audiological evaluation time of 42 min (Range: 39—45), one 8-h workday can be allocated to the ototoxicity monitoring programme for patients with cervical cancer in the current setting. As reflected in Fig. 1, pure tone audiometry, encompassing extended high-frequency audiometry was of the longest duration (19 min), followed by speech audiometry (10 min), while DPOAE testing, immittance audiometry and case history interviews ranged between 3 – 4 min.

| Question                                                                 | Options                        | Clinicians (n = 6) | Oncology Nurses (n = 8) | Pharmacists (n = 9) | Radiotherapists (n = 9) |
|-------------------------------------------------------------------------|--------------------------------|--------------------|-------------------------|---------------------|-------------------------|
| 1. How many patients with cervical cancer did you treat/dispense cisplatin medication to, during the study period? | < 20                           | 0                  | 1 (12.5)                | 4 (44.4)            | 0                       |
|                                                                         | 20–50                          | 2 (33.3)           | 2 (25.0)                | 2 (22.2)            | 1 (11.1)                |
|                                                                         | 50–70                          | 1 (16.7)           | 0                       | 3 (33.3)            | 0                       |
|                                                                         | 70–100                         | 3 (50.0)           | 5 (62.5)                | 0                   | 8 (88.9)                |
| 2. Did you notice any changes in the patient’s hearing?                  | No                             | 2 (33.3)           | 3 (37.5)                | 9 (100)             | 7 (77.8)                |
|                                                                         | Yes                            | 1 (16.7)           | 1 (12.5)                | 0                   | 1 (11.1)                |
|                                                                         | Sometimes                      | 3 (50.0)           | 4 (50.0)                | 0                   | 1 (11.1)                |
| 3. Do you provide patients with information regarding the ototoxic effects of medication? | No                             | 1 (16.7)           | 2 (25)                  | 9 (42.9)            | 7 (77.8)                |
|                                                                         | Yes                            | 4 (66.7)           | 6 (75)                  | 0                   | 1 (11.1)                |
|                                                                         | Sometimes                      | 1 (16.7)           | 0 (0)                   | 0                   | 1 (11.1)                |
| 4. Do you provide patients with any information regarding their hearing? | No                             | 1 (16.7)           | 2 (25.0)                | 9 (100)             | 7 (77.8)                |
|                                                                         | Yes                            | 2 (33.3)           | 3 (37.5)                | 0                   | 1 (11.1)                |
|                                                                         | Sometimes                      | 3 (50.0)           | 3 (37.5)                | 0                   | 1 (11.1)                |
| 5. Do you enquire about patient’s history of hearing difficulties?       | No                             | 0 (0)              | 3 (37.5)                | 9 (100)             | 6 (66.7)                |
|                                                                         | Yes                            | 1 (16.7)           | 1 (12.5)                | 0                   | 1 (11.1)                |
|                                                                         | Sometimes                      | 5 (83.3)           | 4 (50.0)                | 0                   | 2 (22.2)                |
| 6. How many referrals have you made to the audiologist over the last year? | < 20                           | 6 (100)            | 6 (75)                  | 9 (100)             | 9 (100)                 |
|                                                                         | 20–50                          | 0 (0)              | 1 (12.5)                | 0 (0)               | 0 (0)                   |
|                                                                         | 51–70                          | 0 (0)              | 1 (12.5)                | 0 (0)               | 0 (0)                   |
| 7. Do you feel that the ototoxicity monitoring program is beneficial?    | No                             | 0 (0)              | 0 (0)                   | 2 (22.2)            | 1 (11.1)                |
|                                                                         | Yes                            | 6 (100)            | 8 (100)                 | 7 (77.8)            | 8 (88.9)                |
| 8. Was the team approach to managing the patient with cervical cancer successful? | No                             | 1 (16.7)           | 0 (0)                   | 7 (77.8)            | 1 (11.1)                |
|                                                                         | Yes                            | 2 (33.3)           | 6 (75)                  | 0 (0)               | 3 (33.3)                |
|                                                                         | Sometimes                      | 3 (50.0)           | 2 (25.0)                | 2 (22.3)            | 5 (55.6)                |
The approximate costs of equipment required for an ototoxicity monitoring programme was US$ 56,700 (Table 4). The additional expense that would be incurred by the service provider would entail the annual salary cost of an audiologist for the sole purpose of ototoxicity monitoring based on the 2021 remuneration scale of the South African National Department of Health (US$ 26,250).

Costs incurred for unemployed patients and those receiving old age grants approximated US$38, as reflected in Table 5 whilst patients in employment incurred costs approximating US$ 98, due to loss of daily income and transport costs.

Appropriateness

Infrastructure considerations

Responses from both patients and healthcare personnel aided in formulating a set of key considerations pertaining to infrastructure, related to the monitoring programme (Table 6). Accessibility to the healthcare facility/monitoring programme was a key aspect for

---

**Table 3** Key Patient and Healthcare Personnel considerations for a locally responsive ototoxicity monitoring programme

| Patient Considerations | Healthcare Personnel Considerations |
|------------------------|-------------------------------------|
| • Synchronizing audiology appointments with other medical appointments to the same facility | • Information sharing session where the roles of healthcare personnel within the programme are clearly delineated |
| • Communication in indigenous language (isiZulu) | • Communication to patients in local indigenous language (isiZulu) |
| • Pre-treatment counselling for educating, informing and creating awareness on hearing loss and the value of early intervention; and for quelling uncertainties/fears associated with audiological procedures | • Cohesive team approach for patient referrals for baseline and follow-up audiological assessments |
| • Comfort breaks during audiological testing | • Provision of written feedback to clinicians in respect of patients’ audiological assessment results, promoting a collaborative relationship between the Departments of Oncology and Audiology |
| • Efficient referral network for other clinical/supportive care, e.g. ENT, psychologist | • Ototoxicity information to patients made patients more responsive and increased compliance in programme |

---

**Table 4** Costs of equipment required for ototoxicity monitoring

| Equipment                                      | Cost Estimate (US$) |
|-----------------------------------------------|---------------------|
| Otoscope                                       | 200                 |
| Immittance meter                              | 8,800               |
| Pure tone audiometer with high-frequency capability | 9,500               |
| Diagnostic OAE                                | 21,000              |
| Soundproof booth                              | 17,200              |
| **TOTAL**                                     | **56,700**          |

---

**Fig. 1** Average duration of each audiological procedure

---

Costs incurred in the implementation of- and attendance to- an ototoxicity monitoring programme

The approximate costs of equipment required for an ototoxicity monitoring programme was US$ 56,700 (Table 4). The additional expense that would be incurred by the service provider would entail the annual salary cost of an audiologist for the sole purpose of ototoxicity monitoring based on the 2021 remuneration scale of the South African National Department of Health (US$ 26,250).

Costs incurred for unemployed patients and those receiving old age grants approximated US$38, as reflected in Table 5 whilst patients in employment incurred costs approximating US$ 98, due to loss of daily income and transport costs.

Appropriateness

Infrastructure considerations

Responses from both patients and healthcare personnel aided in formulating a set of key considerations pertaining to infrastructure, related to the monitoring programme (Table 6). Accessibility to the healthcare facility/monitoring programme was a key aspect for
patients. In addition, patients also expressed the need for a ‘fit-for-purpose’ environment, given the emotional stress from their treatment and related side effects of chemotherapy. From an audiological perspective, infrastructure designated for the programme and well-functioning, calibrated instruments were key aspects.

**Ototoxicity monitoring protocol assessment**

Significant ototoxic change, as defined by ASHA [14] and AAA [22], was identified in all participants (100%) at the mid-cycle follow-up evaluation. The NCI-CTCAE grading criteria for assessing the adverse effect on hearing ability [35] revealed a shift in severity among 67 (83.8%) participants at the end of the 6-month post treatment evaluation, with a Grade 1 change being the most prevalent ($n = 47$, 58.8%). The comparison of test characteristics revealed that oto-acoustic emissions and word recognition score for right and left ears, respectively, presented with a high specificity (range 77.78% – 100%), whilst the sensitivity was extremely poor (range 1.45% – 22.39%) (Table 7).

Pure tone audiometry (reflected in Table 8) revealed sensorineural hearing loss to be most common at each audiological evaluation with mild hearing loss being the most common in the left ear, and mild-to-moderate hearing loss being the most common in the right ear at each audiological assessment.

| Table 5 | Estimates of patient-related costs for attendance to the ototoxicity monitoring programme (five visits) |
|---------|-------------------------------------------------------------------------------------------------|
|         | Income loss per patient [Minimum wage per hour(US$1.5) × 8 h × 5 visits] | Transport per patient (US$ 7.60 per visit) | Total per patient |
| Unemployed | US$ 38 | US$ 38 | US$ 38 |
| Old age grant recipient | US$ 38 | US$ 38 | US$ 38 |
| Domestic worker/Day labourer | US$60 | US$ 38 | US$ 98 |

| Table 6 | Infrastructure considerations for a locally responsive ototoxicity monitoring programme |
|---------|-----------------------------------------------------------------------------------|
| • The programme should be accessible by public transport |
| • Free/Subsidised hospital transport from referring hospitals |
| • Additional use of golf-carts for internal transport of patients |
| • A quiet, comforting waiting area |
| • Close proximity of ablution facilities especially for patients experiencing nausea and gastrointestinal disturbances |
| • A designated soundproof booth for ototoxicity monitoring |
| • A sound proof booth large enough for accommodating patients in wheelchairs |
| • Necessary audiological test equipment in good working order, with annual calibration records |

| Table 7 | Comparison of audiological assessments and test characteristics in ototoxicity monitoring |
|---------|------------------------------------------------------------------------------------|
| **AUDILOGICAL ASSESSMENTS** | Mid-cycle | 1-month post-treatment | 3-month post-treatment | 6-month post-treatment |
| Ototoxic hearing loss (ASHA)—n (%) | 80 (100) | 50 (62.5) | 30 (37.5) | 13 (16.3) |
| NCI-CTCAE grading scale—n (%) | | | | |
| No Change | 77 (96.2) | 3 (3.8) | 0 (0) | 0 (0) |
| Grade 1 | 3 (3.8) | 25 (32.3) | 4 (5.0) | 1 (1.3) |
| Grade 2 | 0 (0) | 5 (6.3) | 6 (7.5) | 11 (13.8) |
| Grade 3 | 0 (0) | 6 (7.5) | 11 (13.8) | |
| **TEST CHARACTERISTICS** | Sensitivity | Specificity |
| Oto-acoustic Emissions – Right | 26.09% | 77.78% |
| Left | 22.39% | 81.82% |
| Word Recognition Score – Right | 1.45% | 100% |
| Left | 2.99% | 90.91% |

* Comparisons were undertaken, using pure tone audiology as the gold standard to detect ototoxic change at 6-month post treatment.
Discussion

Our study is the first to inform the implementation of a locally responsive ototoxicity monitoring programme through the assessment of acceptability and appropriateness. The programme was well-received, as most participants (89%) reported it as being beneficial. The programme created greater awareness amongst healthcare personnel resulting in a larger number of referrals to the audiologist. However, informing patients about the ototoxic effects of medication, or enquiring about their hearing difficulties was not prioritized, as reflected by both healthcare personnel and patient reports. These findings further concur with Khoza-Shangase and Masondo [21] as well as Al-Malky [18], who similarly reported that referrals were only made once a patient complained of a hearing loss. Possible reasons for the lack of co-operation of all health care personnel may include large caseloads and hectic schedules [21].

A multidisciplinary team approach is considered most effective for the success of an ototoxicity monitoring programme, and the effectiveness of this approach is generally determined by the dedication and cohesivity of the team members. While most healthcare personnel displayed a positive attitude towards monitoring of a patient’s hearing, nurses were initially reluctant due to the invisible nature of a hearing loss and the fear of an increased workload. This reluctance was however minimized and further circumvented by encouraging a collaborative, cohesive and interconnected relationship. The key to developing effective collaborative partnerships is that both partners have common fundamental knowledge and skills and share a common philosophy.

Table 8 Results of Pure Tone Audiometry

|                      | Baseline | Mid-cycle | One month post treatment | Three-month post treatment | Six-month post treatment |
|----------------------|----------|-----------|--------------------------|---------------------------|-------------------------|
| **Number of participants presenting with hearing loss, n (%)** |          |           |                          |                           |                         |
| Both ears            | 17 (20.7)| 21 (25.6) | 24 (29.2)                | 24 (29.2)                 | 31 (37.8)               |
| Left ear only        | 6 (7.3)  | 7 (8.5)   | 4 (4.9)                  | 10 (12.2)                 | 10 (12.2)               |
| Right ear only       | 5 (6.1)  | 6 (7.3)   | 6 (7.3)                  | 5 (6.1)                   | 3 (3.7)                 |
| **Degree of Hearing Loss, n (%)** |          |           |                          |                           |                         |
| Right ear            |          |           |                          |                           |                         |
| Normal               | 60 (73.2)| 55 (67.1) | 51 (62.2)                | 51 (63.8)                 | 46 (56.1)               |
| Mild                 | 8 (9.8)  | 8 (9.8)   | 11 (13.4)                | 8 (9.8)                   | 11 (13.4)              |
| Mild-to-moderate     | 7 (8.5)  | 9 (11.0)  | 9 (11.0)                 | 12 (14.6)                 | 13 (15.9)              |
| Mild-to-moderate-severe | 5 (6.1)  | 7 (8.5)   | 5 (6.1)                  | 6 (7.3)                   | 6 (7.3)                 |
| Mild-to-severe       | 1 (1.2)  | 0 (0)     | 1 (1.2)                  | 1 (1.3)                   | 1 (1.3)                 |
| Mild-to-profound     | 1 (1.2)  | 0 (0)     | 1 (1.2)                  | 1 (1.3)                   | 1 (1.3)                 |
| Moderate-to-moderate-severe | 0 (0)   | 0 (0)     | 0 (0)                    | 1 (1.3)                   | 1 (1.3)                 |
| Moderate-to-profound | 0 (0)    | 1 (1.2)   | 1 (1.2)                  | 1 (1.3)                   | 1 (1.3)                 |
| Left ear             |          |           |                          |                           |                         |
| Normal               | 59 (72)  | 54 (65.9) | 53 (64.6)                | 46 (57.5)                 | 41 (51.3)              |
| Mild                 | 8 (9.8)  | 11 (13.4) | 10 (12.2)                | 17 (20.7)                 | 16 (19.5)              |
| Mild-to-moderate     | 6 (7.3)  | 8 (9.8)   | 9 (11.0)                 | 7 (8.6)                   | 8 (9.8)                |
| Mild-to-moderately-severe | 3 (3.7)  | 4 (4.9)   | 4 (4.9)                  | 6 (7.3)                   | 9 (11.0)              |
| Mild-to-severe       | 3 (3.7)  | 3 (3.7)   | 3 (3.7)                  | 3 (3.7)                   | 3 (3.7)                |
| Moderate             | 1 (1.2)  | 0 (0)     | 0 (0)                    | 0 (0)                     | 0 (0)                  |
| Moderate-to-moderately-severe | 0 (0) | 0 (0)     | 0 (0)                    | 0 (0)                     | 2 (2.4)                |
| Severe-to-profound   | 2 (2.4)  | 2 (2.4)   | 1 (1.2)                  | 1 (1.2)                   | 1 (1.2)                |
| **Types of Hearing Loss** |          |           |                          |                           |                         |
| Sensorineural        |          |           |                          |                           |                         |
| Right ear            | 21 (25.6)| 25 (30.5) | 28 (34.1)                | 28 (34.2)                 | 33 (40.2)              |
| Left ear             | 22 (26.8)| 27 (32.9) | 27 (32.9)                | 34 (41.5)                 | 39 (47.6)              |
| Mixed                |          |           |                          |                           |                         |
| Right ear            | 1 (1.2)  | 2 (2.4)   | 1 (1.2)                  | 1 (1.2)                   | 1 (1.2)                |
| Left ear             | 1 (1.2)  | 1 (1.2)   | 0 (0)                    | 0 (0)                     | 0 (0)                  |
regarding the outcome of their services [37]. While the in-service training may have improved the healthcare personnel's knowledge regarding ototoxicity monitoring, their direct observations of the benefit of such a programme assisted in changing their attitudes. Audiologists should be the principal team member, leading efforts to implement an ototoxicity monitoring programme through the education of healthcare personnel who manage cancer patients receiving ototoxic medication, not only on the auditory effects but more especially its impact on a patient's quality of life [16]. Highlighting the need, within a burden of disease perspective and the societal value of such a programme is key to acceptance from all relevant stakeholders to ensure a successful implementation and maintenance of an ototoxicity monitoring programme [20].

Buy-in from patients with cancer requires consideration of their context in terms of time and financial implications. A full audiological evaluation for ototoxicity in the current study lasted approximately 42 min. Despite more than half the patient cohort reporting the duration of the audiological testing being too long, they all attended follow-up visits. This compliance with the ototoxicity monitoring programme can be attributed to appropriate referrals [13] and counselling provided at all audiological evaluations. In addition, compliance with audiological recommendations were observed, highlighting that patients were taking responsibility for their hearing and that a true partnership was evolving in respect of their hearing health. This was further demonstrated by patients rescheduling audiological appointments that they could not honour due to employment commitments.

Inconsistent referrals to the ototoxicity monitoring programme may be addressed through an alternate method of identifying patients commencing with cisplatin chemotherapy, as baseline assessments should occur before or within 24 h of the first dose of treatment [18]. A suggestion proposed to address this challenge includes the participation of audiologists participating in oncology multidisciplinary team clinics [13]. Referrals from pharmacists in the current context were not deemed feasible due to the use of paper-based systems, making the identification of at-risk patients difficult. Therefore, in such circumstances, liaison with the radiotherapists assisted in the identification of patients not initially referred for baseline assessments, as patients with cervical cancer receive concomitant daily radiotherapy, which commences before the administration of the cisplatin chemotherapy. A transition to electronic medical records [38] may be a way to improve referrals as it would alert the pharmacist when an ototoxic medication has been prescribed, or when a patient is receiving multiple such medication. Furthermore, this study being within a public sector hospital meant a greater reliance on extensive ward stock that are not individually labelled for specific patients [38], thus increasing the difficulty of identifying patients receiving ototoxic medication. Oncology nursing staff were also helpful in this regard as they are often aware of patients receiving cisplatin medication and the approximate start date of treatment [12].

Another limitation related to scheduling the audiological evaluation on the same day as other medical appointments are the time constraints because patients may not always have the flexibility to wait for the audiological evaluation. Therefore, allocating a specific time slot for each patient may be more feasible. Additionally, selecting
the most appropriate tests for the audiological evaluation may also reduce the test time. Extended high-frequency audiometry is undoubtedly the most critical audiological test that should not be omitted, as this frequency range is the most sensitive for the early detection of hearing loss [14, 22]. This consequently led to the development of the sensitive region for ototoxicity (SRO) [39], which may assist in reducing patient test time. The SRO is “the highest frequency with a threshold at or below 100 dB Sound Pressure Level (SPL) followed by the next six lower adjacent frequencies in 1/6-octave steps or the one-octave range near the highest audible frequency” [40]. With 94% sensitivity in detecting ototoxic change, whether in the conventional [41] or extended frequency range [42], the SRO is a valuable tool. Despite its benefit of a rapid test time, the SRO was not included in the current study, as it has been omitted from ASHA, AAA, and HPCSA protocols probably due to a lack of equipment availability [39].

Another audiological test considered excellent for ototoxic monitoring is DPOAE testing. It is noted for its objective, frequency-specific nature, quick administration, and ability to reveal subclinical cochlear damage before pure tone thresholds are affected [16]. In the current study DPOAEs were not sensitive in detecting significant ASHA ototoxic change. The current authors postulate that these results may be due to most participants in the study presenting with normal hearing or mild to moderate degrees of hearing loss in the conventional frequency range, and DPOAEs are not as sensitive to slight or mild hearing losses [43]. Furthermore, the DPOAE measurement was possibly limited to the conventional frequency range, while a significant ototoxic change in the current study was most evident in frequencies above 8000 Hz, and the DPOAE equipment used in the current study could assess up to 6000 Hz. Therefore, it is advisable to ensure that DPOAE equipment utilised for ototoxicity monitoring has the capability of assessing at least up to 10 000 Hz, as higher DPOAE frequencies have been reported to be statistically more sensitive to early ototoxicity than lower DPOAE frequencies [44].

Whilst DPOAE testing is encouraged at all audiological evaluations, speech audiometry (incorporating speech reception threshold and word recognition score) is conducted at the baseline assessment and when there is a significant change in air conduction thresholds [16]. The sensitivity of word recognition score testing in detecting a significant ototoxic change in the current study reflects that this test does not significantly contribute to the diagnosis of ototoxic hearing loss. A possible postulation about why word recognition scores are a poor indicator of ototoxicity includes the use of monitored live voice testing instead of recorded speech material. Despite the many disadvantages of monitored live voice testing [45], this method of presentation was utilized due to the lack of the necessary equipment at the study site, a common issue affecting many institutions in limited resource environments. Furthermore, with the results of speech audiometry often being used to counsel patients about the impact of hearing loss on communication [16], it is imperative that speech audiometry is conducted in noisy and quiet conditions [8]. While speech in noise tests are not commonly utilized during ototoxicity monitoring [14, 22], its inclusion in the test battery would be beneficial in determining or predicting real world difficulties likely to be experienced by patients with cancer and would therefore assist in planning appropriate rehabilitation [8]. In the current study, speech audiometry was conducted at all audiological evaluations and added approximately 10 min to the session. Considering the poor sensitivity and specificity of speech (in quiet) audiometry, the HPCSA [15] has not recommended its inclusion in the monitoring audiometry. Therefore, the current authors recommend the investigation of the inclusion of speech in noise testing during ototoxicity monitoring, given the reasons highlighted above.

However, HPCSA [15] recommends bilateral otoscopic examination, bilateral pure-tone air conduction testing, and bilateral DPOAEs conducted bi-weekly during treatment. Conducting the full audiological test battery at each audiological evaluation is time-consuming, as reported by most participants, highlighting the need to modify the test battery [16]. Konrad-Martin et al. [13] also revealed that multiple comprehensive audiological evaluations were not feasible for monitoring assessments, even for responsive patients. Therefore, a more workable option may be a weekly evaluation prior to receiving cisplatin treatment, as suggested by ASHA [14] and AAA [22] so that significant ototoxic change is detected to allow early treatment modifications within the ambit of practice guidelines and appropriate audiological interventions.

Whilst all patients were identified with ototoxicity at their mid-cycle follow-up, further assessment using the NCI-CTCAE criteria aided in the grading of severity. This approach, in line with the HPCSA [15], allowed for an evidence-informed approach to aural rehabilitation to mitigate the functional impact that the degree of hearing loss can have on a patient’s communication [16]. The need for coherently and meaningfully communicating a patient’s audiological assessment results to the necessary stakeholders was key in ensuring early patient-specific therapeutic interventions [46]. In addition, providing feedback to patients with minimal jargon also encouraged compliance to the recommendations made.
In the current study, the strategy of ‘creative scheduling’ (during lunch breaks and before the audiology clinic official hours) and having at least two blank appointments each day were adopted to accommodate for baseline assessments or patients who were delayed for their appointments or had many appointments on a day. This plan was suitable for the current study due to patients with cervical cancer only being assessed; however, it may not work for an ototoxicity monitoring programme that caters for all patients receiving cisplatin chemotherapy at the facility. Therefore, it is advisable for the ototoxicity monitoring programme to be set up in a location close to the chemotherapy treatment room, or use portable equipment such as that used in teleaudiology, namely the KuduWave [47] or OtoID [48], which may address some of the challenges of the conventional audio-logical ototoxicity monitoring programme.

This study, while having the advantage of reporting on real world practice, is not without limitations. Being a single site study, the findings of this study have limited generalizability, perhaps to similar environments looking to initiate such programmes and highlights the need for more engagement on this topic. Further studies, exploring key attributes to enhance the success of such programmes, highlight the barriers, gaps and local needs not identified/investigated in this study, are required to build on the evidence base. This can be achieved through further qualitative research methodologies such as one-on-one and focus group interviews, which would allow for data enrichment and data saturation. This would also promote robust dialogue and encourage a sharing of experiences on best practices within similar resource settings, resulting in greater mobility for alignment with the recommendations of the World Health Organization [49] of making ear and hearing care part of universal health coverage.

Conclusion
This study is the first to comment on the feasibility of ototoxicity monitoring in South Africa that has reflected the realities of our community and practice setting. It provides insight for a contextually responsive programme within the scope of the HPCSA guidelines and can serve as a potential roadmap for other limited resource environments considering the implementation, adaptation, integration or expansion of such a program. The study revealed that an ototoxicity monitoring programme is feasible through meaningful dialogues and partnerships with- and considerations from- both patients and health care providers regarding planning, delineation of responsibilities and cost implications. Whilst the need for protocol refinement is another area that requires a greater depth of discussions, it is abundantly clear that an established and well-functioning ototoxicity monitoring programme allows for a proactive hearing health promotion culture, allowing for the early identification of ototoxic hearing loss and subsequent rehabilitation of the unavoidable hearing loss, and its benefits therefore outweigh its costs.

Abbreviations
AAA: American Academy of Audiology; ASHA: American Speech-Language-Hearing Association; DPOAE: Distortion product otoacoustic emission; HPCSA: Health Professions Council of South Africa; HIV: Human Immunodeficiency Virus; LMIC: Low-Middle Income countries; SRT: Speech recognition threshold; WRS: Word recognition score/ speech discrimination.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-08099-8.

Acknowledgements
The South African Medical Research Council, National Department of Health, Oticon Foundation, and the University of KwaZulu-Natal are hereby acknowledged for financial support.

Authors’ contributions
JP conceived the study, conducted data collection, clinically analyzed the data and drafted the manuscript. VS finalised the statistical analysis of data. VS, MP, and CDG supervised the study, provided critical input and contributed to the drafting of the manuscript. All authors read and approved the final manuscript.

Funding
Funding for the study has been received from the South African Medical Research Council of South Africa in terms of the National Health Scholarship Programme provided for this purpose by the National Department of Health, the Oticon Foundation as well as the University of KwaZulu-Natal.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study has been conducted in accordance with the Declaration of Helsinki and has been approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 066/13) and the study site before data collection commenced. Informed consent was obtained from all participants prior to data collection. Participants were informed as to the nature, and the purpose of the study, any potential risks that may be involved, participation is voluntary, the nature of their participation, their right to withdraw at any time if they so desired, and that refusal to participate did not affect their clinical care. Furthermore, patients were assured of strict confidentiality and anonymity, as all participants were allocated numbers. This information, relayed in the information and consents documents were available in English and isiZulu, taking into consideration the demographic and language profile of the country.

Consent for publication
Not Applicable.

Additional file 1. CID W22 auditory test wordlist for word recognition score testing for English speaking participants.

Additional file 2. Word recognition score wordlist for isiZulu speaking participants.

Author details
1 Department of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
2 School of Health Sciences, Human Medicine, University of KwaZulu-Natal, Durban, South Africa.
3 Department of Otorhinolaryngology Head and Neck Surgery, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
4 Department of Social Work, Community and Health Services, University of KwaZulu-Natal, Durban, South Africa.
5 Department of Health Informatics, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Supplementary Information
This article contains the supplementary material available at https://doi.org/10.1186/s12913-022-08099-8.

Additional file 1. CID W22 auditory test wordlist for word recognition score testing for English speaking participants.

Additional file 2. Word recognition score wordlist for isiZulu speaking participants.

Acknowledgements
The South African Medical Research Council, National Department of Health, Oticon Foundation, and the University of KwaZulu-Natal are hereby acknowledged for financial support.

Authors’ contributions
JP conceived the study, conducted data collection, clinically analyzed the data and drafted the manuscript. VS finalised the statistical analysis of data. VS, MP, and CDG supervised the study, provided critical input and contributed to the drafting of the manuscript. All authors read and approved the final manuscript.

Funding
Funding for the study has been received from the South African Medical Research Council of South Africa in terms of the National Health Scholarship Programme provided for this purpose by the National Department of Health, the Oticon Foundation as well as the University of KwaZulu-Natal.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study has been conducted in accordance with the Declaration of Helsinki and has been approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 066/13) and the study site before data collection commenced. Informed consent was obtained from all participants prior to data collection. Participants were informed as to the nature, and the purpose of the study, any potential risks that may be involved, participation is voluntary, the nature of their participation, their right to withdraw at any time if they so desired, and that refusal to participate did not affect their clinical care. Furthermore, patients were assured of strict confidentiality and anonymity, as all participants were allocated numbers. This information, relayed in the information and consents documents were available in English and isiZulu, taking into consideration the demographic and language profile of the country.

Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1. Discipline of Audiology, School of Health Sciences, University of KwaZulu- Natal, Private Bag X54001, Durban 4000, South Africa. 2. Speech and Language Therapy, Massey University, Albany (Oteha Rohe) Campus, Building 84, Auckland, New Zealand. 3. African Cancer Institute, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town 8000, South Africa.

Received: 28 June 2021 Accepted: 16 May 2022
Published online: 18 June 2022

References
1. World Health Organization. Deafness and hearing loss. Geneva; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss.
2. World Health Organization. Addressing the rising prevalence of hearing loss. Geneva. 2018. Available from: https://apps.who.int/iris/handle/10665/260336.
3. Watts KL. Otoxicity: visualized in concept maps. Semin Hear. 2019;40(2):177–82.
4. Ganesan P, Schmijedje J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Otoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;8(2):59–68.
5. Stein N, Swanepoel DW. Sensory and neural auditory disorders associated with HIV/AIDS. In: Swanepoel DW, Louw B, editors. HIV/AIDS Related Communication, Hearing and Swallowing Disorders. San Diego: Plural Publishing; 2010. p. 243–88.
6. Jodon AS, Bhadauriya P, Sharma M. An integrative review of Cisplatin: the first metal anti-tumor drug. J Drug Deliv Ther. 2019;9(3):673–7.
7. Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: Add high-frequency audiometry in the first metal anti-tumor drug therapy. 1994. Available from: https://www.asha.org/policy/gl1994-00003/.
8. Moodley L, Louw B, Hugo R. Early identification of at-risk infants and toddlers: a transdisciplinary model of service delivery. S Afr J Commun Disord. 2000;47:25–39.
9. Hall JW. Handbook of otoacoustic emissions. San Diego: Singular Publishing; 1991.
10. Kirk A, Gilmour S. Otoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;8(2):59–68.
11. Jodon AS, Bhadauriya P, Sharma M. An integrative review of Cisplatin: the first metal anti-tumor drug. J Drug Deliv Ther. 2019;9(3):673–7.
12. Fausti SA, Henry JA, Helt WJ, Phillips DS, Frey RH, Noffsinger D, et al. An early identification of at-risk infants and toddlers: a transdisciplinary model of service delivery. S Afr J Commun Disord. 2000;47:25–39.
13. Gray A, Riddin J, Jugathpal J. Health care and pharmacy practice in South Africa. Can J Hosp Pharm. 2016;69(1):36–41.
14. Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):181–100.
15. Fausti SA, Helt WJ, Gordon JS. Audiologic monitoring for ototoxicity and patients management. In: Pharmacology and ototoxicity for audiologists. United States: Thomson Delmar Learning; 2007. p. 230–51.
16. Fausti SA, Helt WJ, Phillips DS, Gordon JS, Bratt GW, Sugiuara KM, et al. Early detection of ototoxicity using 1/6th-octave steps. J Am Acad Audiol. 2003;14(8):444–50.
17. Jeffers L, Verker K, DeBierne GA, Kelly-Campbell R, Gibb D, Bird P. The current state of ototoxicity monitoring in New Zealand. N Z Med J. 2014;127(1398):84–97.
18. Al-Malky G. Audiological monitoring in ototoxicity - are we doing enough? ENT and Audiology News. 2016;2(5).
19. de Andrade V, Khoza-Shangase K, Hajat F. Perceptions of oncologists at two state hospitals in Gauteng regarding the ototoxic effects of cancer chemotherapy: a pilot study. Afr J Pharm Pharmacol. 2009;3(6):307–18.
20. Paken J, Govender CD, Pillay M, Sewram V. Perspectives and practices of ototoxicity monitoring. S Afr J Commun Disord. 2020;67(1):e1–10.
21. Khoza-Shangase K, Masondo N. What are the current audiologic practices for ototoxicity assessment and management in the South African healthcare context? Int J Environ Res Public Health. 2020;17(7):2613. Available from: http://eurpub.com/archives/ISED/32290287.
22. American Academy of Audiology. American Academy of Audiology Position Statement and guidelines: Otoxicity monitoring. 2009. Available from: https://audiology-web3s.amazonaws.com/migrated/OtoMonGuidelines.pdf.539974c40999c1.58842217.pdf.
23. Pillay M, Tiwari R, Kathard H, Chikte U. Sustainable workforce: South African Audiologists and Speech Therapists. Hum Resour Health. 2020;18(1):47.
24. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
25. Global Cancer Observatory: Cancer Tomorow. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/tomorrow. Accessed 25 May 2021.
26. Neuman LW. Social research methods: qualitative and quantitative approaches. 7th ed. Boston: Allyn and Bacon, 2011.
27. Deqgs D, Hernandez F. Enhancing the value of qualitative field notes through purposeful reflection. Qual Rep. 2018;23(10):2552–60.
28. Feldman AS. Acoustic impedance-admissibility battery. In: Katz J, editor. Handbook of clinical audiology. 2nd ed. Baltimore: Williams and Wilkins Company; 1978. p. 356–74.
29. Republic of South Africa. Government Gazette No.44136. Department of Employment and Labour. 2021;668(44136). Available from: https://www.gpwonline.co.za/Gazettes/Pages/Published-Separate-Gazettest.aspx?p=17, Accessed 25 May 2021.
30. Northern J, Grimes AM. Introduction to acoustic impedance. In: Katz J, editor. Handbook of clinical audiology. 2nd ed. Baltimore: Williams and Wilkins Company; 1978. p. 344–55.
31. Silman S, Silverman CA. Auditory diagnosis: principles and applications. San Diego: Academic Press; 1991.
32. Hodgson WR. Basic audiological evaluation. Baltimore: Williams and Wilkins, 1980.
33. Bhatia SS, Prabhakaraiah L, Singh R. Otoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;8(2):59–68.
34. Hall JW. Handbook of otoacoustic emissions. San Diego: Singular Publishing; 1991.
35. Hodgson WR. Basic audiological evaluation. Baltimore: Williams and Wilkins, 1980.
36. Appana D, Joseph L, Paken J. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal. S Afr J Commun Disord. 2016;63(1):154.
37. Hall JW. Handbook of otoacoustic emissions. San Diego: Singular Publishing; 2000.
38. National Cancer Institute. Cancer therapy evaluation program, common terminology criteria for adverse events, version 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
39. Richards L. Qualitative teamwork: Making it work. Qual Health Res. 1999;9:7–10.
40. Moody L, Louw B, Hugo R. Early identification of at-risk infants and toddlers: a transdisciplinary model of service delivery. S Afr J Commun Disord. 2000;47:25–39.
41. Fausti SA, Helt WJ, Gordon JS. Audiologic monitoring for ototoxicity and patients management. In: Pharmacology and ototoxicity for audiologists. United States: Thomson Delmar Learning; 2007. p. 230–51.
42. Fausti SA, Helt WJ, Phillips DS, Gordon JS, Bratt GW, Sugiuara KM, et al. Early detection of ototoxicity using 1/6th-octave steps. J Am Acad Audiol. 2003;14(8):444–50.
43. Fausti SA, Henry JA, Helt WJ, Phillips DS, Frey RH, Noffsinger D, et al. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear. 2019;20(6):497.
44. Moodley L, Louw B, Hugo R. Early identification of at-risk infants and toddlers: a transdisciplinary model of service delivery. S Afr J Commun Disord. 2000;47:25–39.
43. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 1994;15(3):232–9.
44. Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, et al. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear. 2011;32(1):61–74.
45. Brandy WT. Speech audiometry. In: Katz J, editor. Handbook of Clinical Audiology. 5th ed. USA: Lippincott Williams and Wilkins; 2002. p. 96–110.
46. King KA, Brewer CC. Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making. Int J Audiol. 2018;57(sup4):S19–28.
47. Brennan-Jones CG, Eikelboom RH, de Swanepoel W, Friedland PL, Atlas MD. Clinical validation of automated audiometry with continuous noise-monitoring in a clinically heterogeneous population outside a sound-treated environment. Int J Audiol. 2016;55(9):S19–28.
48. Dille MF, McMillan GP, Helt WJ, Konrad-Martin D, Jacobs P. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment. J Am Acad Audiol. 2015;26(9):750–60.
49. World Health Organization. World report on hearing: Geneva. 2021. Available from https://cdn.who.int/media/docs/default-source/documents/health-topics/deafness-and-hearing-loss/world-report-on-hearing/wrh-executive-summary.pdf?sfvrsn=feb8d533_30&download=true.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.